Based on the findings, it can be concluded that the bioactive secondary metabolites present in PK have the potential to treat diabetes and dyslipidemia through various mechanisms, such as increasing insulin secretion, inhibiting intestinal alpha-glucosidase, and activating glucokinase. The gene discussed is GAA; the disease is metabolic syndrome.